← Back to Search

Anti-tumor antibiotic

CX-2051 for Solid Tumors

Phase 1

Recruiting

Research Sponsored by CytomX Therapeutics

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Metastatic or locally advanced unresectable solid tumor that has progressed after standard therapy

Eastern Cooperative Oncology Group (ECOG) performance status of 0-1

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 60 months

Awards & highlights

Study Summary

This trial aims to test the safety and effectiveness of a new drug called CX-2051 in adults with advanced solid tumors.

Who is the study for?

This trial is for adults with advanced solid tumors who have not responded to standard treatments. Specific eligibility details are not provided, but typically participants must be in good overall health aside from their cancer and able to comply with study requirements.Check my eligibility

What is being tested?

The trial is testing CX-2051, a new potential treatment for solid tumors. As it's the first time this drug is being used in humans, the focus will be on assessing its safety, how well patients tolerate it, and any signs of effectiveness against the tumors.See study design

What are the potential side effects?

Since this is a first-in-human study for CX-2051, exact side effects are unknown. Generally, such trials monitor for common cancer treatment side effects like fatigue, nausea, skin reactions or allergic responses.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

My cancer has spread and cannot be removed by surgery, and it has gotten worse after treatment.

Select...

I am fully active or can carry out light work.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 60 months

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~60 months

This trial's timeline: 3 weeks for screening, Varies for treatment, and 60 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Determine the recommended Phase 2 dose (RP2D)

Safety and tolerability of CX-2051

Secondary outcome measures

Disease control rate (DCR)

Duration of disease control (DODC)

Duration of response (DOR)

+3 more

Trial Design

1Treatment groups

Experimental Treatment

Group I: CX-2051Experimental Treatment1 Intervention

0 / 2Eligibility criteria met

Find a Location

Who is running the clinical trial?

CytomX TherapeuticsLead Sponsor

7 Previous Clinical Trials

760 Total Patients Enrolled

Monika Vainorius, MDStudy DirectorCytomX Therapeutics

5 Previous Clinical Trials

309 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is the current clinical trial actively enrolling participants?

"According to information on clinicaltrials.gov, recruitment for this research has ceased. The trial was initially listed on 3/31/2024 and last updated on 2/12/2024. Despite the closure of this specific study, there are currently 2601 other trials actively seeking participants."

Answered by AI

What are the principal goals that this medical study aims to achieve?

"The primary aim of this clinical investigation, which spans approximately 44 months, is to evaluate the safety and tolerance of CX-2051. Secondary endpoints encompass the Duration of Response (DOR), characterized as the duration from initial confirmation of complete response (CR) or partial response (PR) per RECIST v1.1 criteria to disease progression or death during the study period; Overall Survival (OS), indicating the time from commencement of treatment to decease regardless of cause; and Objective Response Rate (ORR), reflecting the percentage of participants achieving CR or PR based on Investigator evaluation using RECIST v1.1 guidelines."

Answered by AI

Has CX-2051 received the stamp of approval from the FDA?

"Given that this is a Phase 1 trial with scarce data backing its safety and efficacy, CX-2051 has been rated as a 1 on the safety scale by our team at Power."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

First In Human Study of CX-2051 in Advanced Solid Tumors

2024. "First In Human Study of CX-2051 in Advanced Solid Tumors". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT06265688.

All > Paid Studies Boston > Greensboro